Group Achievements

The Taskén Group was established at the Institute of Basic Medical Sciences, UiO in 1997 and was part of the Biotechnology Centre of Oslo, UiO from 2003 to 2016 and the Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, UiO/OUH from 2008 to 2018. Since 2018, the group is located at the Institute for Cancer Research at Oslo University Hospital.

Some highlights of the past 20 years include:

  • Publication of more than 300 peer-reviewed papers, with more than 17,000 citations
  • Over 1000 pieces of press coverage about the group activities
  • Inventions leading to more than 20 patent families (5 to 25 countires) and patient applications
  • More than 30 industry collaborations
  • More than 30 PhD students, 30 postdoctoral researchers and 40 MSc/MD/BSc students trained in the group
  • Over 25 clinical observation studies and five clinical intervention studies completed and/or initiated
  • Development and implementation of protein-protein interaction studies (peptide array and Biacore), phosphoproteomics and phospho-flow, immunophenotyping, regulatory T cell assays, chemical biology and cancer drug sensitivity screening technologies
  • Precision medicine implementation through clinical trials (IMPRESS-Norway), infrastructure (InPreD, MATRIX), and international projects (PCM4EU, PRIME-ROSE)
 
Scroll to top